![]() | ![]() |
Formats:
|
||||||||||||||||||||||
Copyright © American Society for Investigative Pathology Accumulation of Citrullinated Proteins by Up-Regulated Peptidylarginine Deiminase 2 in Brains of Scrapie-Infected Mice A Possible Role in Pathogenesis From the Ilsong Institute of Life Science,* Hallym University, Anyang, Republic of Korea; the Department of Microbiology,† College of Medicine, Hallym University, Chuncheon, Republic of Korea; the New York State Institute for Basic Research in Developmental Disabilities,‡ Staten Island, New York; and the Aging Regulation,§ Tokyo Metropolitan Institute of Gerontology, Tokyo, Japan Accepted July 3, 2008. This article has been cited by other articles in PMC.Abstract Peptidylarginine deiminases (PADs), which are a group of posttranslational modification enzymes, are involved in protein citrullination (deimination) by the conversion of peptidylarginine to peptidylcitrulline in a calcium concentration-dependent manner. Among the PADs, PAD2 is widely distributed in various tissues and is the only type that is expressed in brain. To elucidate the involvement of protein citrullination by PAD2 in the pathogenesis of brain-specific prion diseases, we examined the profiles of citrullinated proteins using the brains of scrapie-infected mice as a prion disease model. We found that, compared with controls, increased levels of citrullinated proteins of various molecular weights were detected in different brain sections of scrapie-infected mice. In support of this data, expression levels of PAD2 protein as well as its enzyme activity were significantly increased in brain sections of scrapie-infected mice, including hippocampus, brain stem, and striatum. Additionally, the expression levels of PAD2 mRNA were increased during scrapie infection. Moreover, PAD2 immunoreactivity was increased in scrapie-infected brains, with staining detected primarily in reactive astrocytes. Using two-dimensional electrophoresis and matrix-assisted laser desorption/ionization-time of flight mass spectrometry, various citrullinated proteins were identified in the brains of scrapie-infected mice, including glial fibrillary acidic protein, myelin basic protein, enolases, and aldolases. This study suggests that accumulated citrullinated proteins and abnormal activation of PAD2 may function in the pathogenesis of prion diseases and serve as potential therapeutic targets. Accumulation of misfolded proteins, posttranslational modification of proteins, alteration of free ion distribution, and perturbation of cellular redox homeostasis are general features of progressive neurodegenerative disorders. These changes have been observed consistently as part of the neuropathogenesis and neuropathology of prion diseases. Prion diseases are characterized by various neurological symptoms and common histopathological features such as spongiform degeneration of the central nervous system, reactive gliosis, neuronal loss, and, in some cases, formation of amyloid plaques.1 It has been reported that all prion diseases are associated with the aberrant metabolism of prion protein (PrP). Conversion of the cellular prion protein (PrPC) into an abnormal, protease-resistant and infectious isoform (PrPSc) is believed to be a principal molecular basis of prion diseases,2 and the accumulation of PrPSc in the central nervous system is thought to be responsible for neuronal loss and/or astrocytosis.3 In general, the pathogenic mechanisms of neurodegenerative disorders are not fully delineated; prion diseases are no exception to this uncertainty. Alteration of intracellular calcium (Ca2+) distribution and Ca2+-related proteins have a critical role in synaptic dysfunction and neuronal cell death in neurodegenerative diseases. In cultured cells, prion infection induced abnormalities in Ca2+ homeostasis by altering receptor-mediated intracellular Ca2+ responses,4,5 suggesting a possible role of Ca2+ in the neuronal cell death seen in prion diseases. Peptidylarginine deiminases (PADs) are known to be directly affected by Ca2+ homeostasis and convert peptidylarginine to peptidylcitrulline (protein citrullination or deimination) in a Ca2+ concentration-dependent manner.6,7 This modification of proteins decreases their positive charge resulting in changing the functions of native proteins.8 PADs are found as five different isoforms in various mammalian tissues such as brain, spinal cord, spleen, and skeletal muscle.9 Among them, only PAD type II (PAD2) is expressed in adult rat brains and its cellular localization was found in glial cells.10,11,12 In a very recent report, PAD2 expression was detected in cultured Schwann cells.13 Previous reports indicate that PAD2 is involved in the citrullination of various cerebral proteins under neurodegenerative conditions.14 Recently, it has been reported that the abnormal accumulation of citrullinated proteins including glial fibrillary acidic protein (GFAP) and vimentin were found in Alzheimer’s disease (AD)-afflicted hippocampus; increased expression of PAD2 and its enzyme activity were detected during neurodegenerative changes and were accompanied by impairment of intracellular Ca2+ homeostasis.15 In multiple sclerosis (MS) patients, previous studies have revealed that citrullinated myelin basic protein (MBP) was increased to 45% of total MBP compared to healthy adults16 and has been implicated in the pathological mechanism of MS.17 Therefore, PAD and citrullinated proteins can be used as important factors for the diagnosis of various human diseases.7 To our knowledge, there are no data available regarding citrullination by PAD2 in prion diseases. Here we report for the first time that increased citrullinated proteins including GFAP, MBP, and several newly identified proteins were found in the brains of scrapie-infected mice along with increased expression of PAD2 protein and its enzyme activity. These findings suggest a possible role of citrullination in the induction of pathological changes in the brains of scrapie-infected mice. Materials and Methods Animals and Scrapie Strain C57BL/6J mice, 4 to 6 weeks of age, were obtained from the Experimental Animal Center of Hallym University. The original stock of ME7 scrapie strain was kindly provided by Dr. Alan Dickinson of Agriculture and Food Research Council and Medical Research Council Institute (Edinburgh, UK): this scrapie strain was maintained by serial intracerebral passage of brain homogenate from terminally affected mice. Mice were inoculated intracerebrally with 30 μl of 1% (w/v) brain homogenate in 0.01 mol/L phosphate-buffered saline (PBS) prepared from ME7-injected C57BL mice or from control mice that had been injected with normal brain homogenate. The mice were then sacrificed under 16.5% urethane at 150 ± 10 days after inoculation with ME7 scrapie strain, a time when clinical manifestations of disease were evident. To perform a time course study, brains were also collected at different time points (50, 100, and 150 days after inoculation). Mice inoculated with normal brain homogenate remained healthy throughout the same period. For immunohistochemistry, mice were perfused transcardially with PBS followed by 4% paraformaldehyde in PBS (pH 7.4). The brains were removed immediately, postfixed in the same fixative for 2 hours at room temperature, rinsed with PBS, dehydrated with ethanol, and embedded in paraffin. Western Blot Analysis Brains from control and scrapie-infected mice were homogenized in modified RIPA buffer containing 50 mmol/L Tris-HCl, pH 7.4, 150 mmol/L NaCl, 2 mmol/L ethylenediaminetetraacetic acid, 1% Triton X-100, 1% Nonidet P-40, 0.25% sodium deoxycholate, and protease inhibitors.18 The homogenates were rocked at 4°C for 1 hour and centrifuged at 18,000 × g at 4°C for 10 minutes to remove cell debris. The supernatant was collected and protein concentration was determined with a BCA protein assay kit (Pierce, Rockford, IL). Citrullinated proteins were detected by Western blot analysis as described previously.19 Briefly, equal amounts of protein (50 μg/lane) were subjected to 12% sodium dodecyl sulfate-polyacrylamide gel electrophoresis and transferred to polyvinylidene difluoride membrane using an electrotransfer system (Bio-Rad, Hercules, CA). For detection of citrullinated proteins, citrulline residues on the polyvinylidene difluoride membrane were chemically modified by overnight incubation at 37°C in modification reagent [1 vol of 1% diacetyl monoxime/0.5% antipyrine/1 N acetic acid, and 2 vol of a mixture of 85% H3PO4/98% H2SO4/H2O (20/25/55) containing 0.025% FeCl3].20 The membrane was then blocked with 5% nonfat dry milk in PBST (8 mmol/L Na2HPO4, 2 mmol/L KH2PO4, 138 mmol/L NaCl, 2.7 mmol/L KCl, pH 7.4, 0.05% Tween 20) for 2 hours at room temperature, then probed with an anti-modified citrulline antibody at 1:1000 (Upstate, Lake Placid, NY) in PBST overnight at 4°C. For the detection of other target proteins, the transferred polyvinylidene difluoride membranes were directly probed with either monoclonal anti-PAD2 antibody (1:2000), mouse monoclonal anti-neuron-specific enolase (1:2000) (AbFrontier, Seoul, Republic of Korea), rabbit polyclonal anti-aldolase C (1:1000) (Santa Cruz Biotechnology, Santa Cruz, CA), mouse monoclonal anti-MBP (1:3000) (Abcam, Cambridge, MA), or mouse monoclonal anti-β actin (1:10,000) (Sigma, St. Louis, MO) in 5% nonfat dry milk in PBST. These membranes were then incubated with the appropriate secondary antibody-conjugated to horseradish peroxidase. Bound antibodies were visualized by chemiluminescent substrate as described by the manufacturer (Amersham Biosciences, Piscataway, NJ). Reverse Transcription-Polymerase Chain Reaction (RT-PCR) Total RNA was extracted from brain samples of control and scrapie-infected mice using TRI-reagent (Sigma) according to the manufacturer’s protocols. Complementary DNA (cDNA) was generated using the Moloney murine leukemia virus reverse transcriptase (Promega, Madison, WI) according to the instructions of the manufacturer. RT-PCR was performed using primers specific for the PAD2 (665 bp; forward, 5′-CTGCGGTCTCTGGGTCCTTCCTGTA-3′ and reverse, 5′-GACCAGGCGAGAGAACAGAAATAGC-3′) and β-actin (196 bp; forward, 5′-TGTGATGGACTCCGGTGACGG-3′ and reverse, 5′- ACA GCTTCTCTTTGATGTCACGC-3′) genes. The PCR products were separated by electrophoresis on a 1% agarose gel and visualized under UV light. Measurement of PAD2 Activity The PAD2 activity was determined as described previously.9 Briefly, the reaction mixture containing 100 mmol/L Tris-HCl, pH 7.5, 10 mmol/L CaCl2, 5 mmol/L dithiothreitol, with or without 10 mmol/L benzoyl-l-arginine ethyl ester (Sigma), and 0.5 mg of brain protein in a final volume of 120 μl was incubated at 50°C for 1 hour. After incubation, the reaction was stopped by adding final 1 mol/L perchloric acid. Samples were cooled down on ice for 20 minutes and then centrifuged at 18,000 × g for 5 minutes at room temperature. Aliquots of 120 μl of supernatant were mixed with 380 μl of dH2O and 500 μl of color developing reagent and incubated at 95°C for 15 minutes. The samples were cooled to room temperature and then the absorbance was measured at 540 nm by enzyme-linked immunosorbent assay reader (VersaMax; Molecular Devices, Sunnyvale, CA). Quantification of citrulline was determined by comparison with appropriate standards. One unit of the enzyme is defined as the amount of enzyme that deiminates 1 μmol/L of the substrate (benzoyl-l-arginine ethyl ester) in 1 minute at 50°C. Immunohistochemistry and Double-Immunofluorescence Staining Immunohistochemical procedures were performed using the ABC kit (Vector, Burlingame, CA) by a modification of the avidin-biotin-peroxidase method. Briefly, 6-μm sections of brain were deparaffinized with xylene and hydrated in a graded ethanol series, and then treated with 0.3% hydrogen peroxide in methyl alcohol for 20 minutes to block endogenous peroxidase. The sections were exposed to normal donkey serum (Jackson ImmunoResearch, West Grove, PA), and then incubated with mouse monoclonal antibody for PAD2 (1:500) overnight at 4°C. After washing, the sections were treated sequentially with biotinylated anti-mouse IgG and avidin-biotin-peroxidase complex, developed with diaminobenzidine-hydrogen peroxide solution (0.003% 3,3-diaminobenzidine and 0.03% hydrogen peroxide in 50 mmol/L Tris buffer), and finally counterstained with hematoxylin. For staining of citrullinated proteins, the sections were incubated in modification reagent for 2 hours at 37°C before initiation of the immunohistochemistry protocol. After three washes in PBS buffer, the sections were exposed to 10% normal donkey serum for 1 hour at room temperature and then rabbit polyclonal antibody to modified citrulline (1:4000) for 1 hour at 37°C. The subsequent procedures were performed as described above for PAD2 staining. For double-immunofluorescence staining, the sections were incubated in the following order: 10% normal donkey serum in PBS for 1 hour, rabbit polyclonal anti-PAD2 (1:100)21 overnight at 4°C, lissamine rhodamine sulfonyl chloride (LRSC)-conjugated donkey anti-rabbit IgG (1:200) (Jackson ImmunoResearch) for 1 hour at room temperature, washed, and blocked with 10% normal goat serum in PBS for 1 hour at room temperature and then incubated with various primary antibodies as follows: mouse monoclonal anti-GFAP antisera (1:400; DAKO, Copenhagen, Denmark), mouse monoclonal anti-NeuN (1:50) (Chemicon, Temecula, CA), mouse monoclonal anti-MBP (1:3000) overnight at 4°C and finally washed and incubated with fluorescein isothiocyanate-conjugated goat anti-mouse IgG (1:200) (Jackson ImmunoResearch). For microglia staining, the lectin Griffonia simplicifolia (GSA) was optimized by incubating the sections in 0.5 mg/ml of trypsin in 0.05 mol/L Tris-buffered saline containing 1 mmol/L CaCl2 (pH 7.6) for 5 minutes at 37°C. Biotinylated lectin GSA B4-isolectin (Sigma) was then added for 1 hour at room temperature, followed by fluorescein isothiocyanate-labeled streptavidin (Zymed, San Francisco, CA). The sections were examined with a LSM 510 confocal laser-scanning microscope (Carl Zeiss, Oberkochen, Germany). Two-Dimensional Gel Electrophoresis (2-DE) and Proteome Analysis Protein extraction and 2-DE were performed as reported previously.22 Briefly, 200 μg of brain protein of control and ME7 scrapie-infected mice was dissolved in a rehydration buffer containing 8 mol/L urea, 2% CHAPS, 65 mmol/L dithiothreitol, 0.5% immobilized pH gradient (IPG) buffer (Bio-Rad), 40 mmol/L Tris-HCl, and 0.002% bromophenol blue. The brain homogenates were applied to the IPG Readystrip, 7 cm, pH 3 to 10 linear gradient (Bio-Rad). The IPG strips were rehydrated for 16 hours at 20°C using the PROTEAN isoelectric focusing cell (Bio-Rad) according to the manufacturer’s instructions. Briefly, isoelectric focusing was conducted at 250 V for 15 minutes, linearly increased throughout 2 hours to a maximum of 4000 V, and then run to accumulate a total of 20,000 Vhours. The gel strips were equilibrated before second dimensional electrophoresis for 15 minutes in 50 mmol/L Tris-HCl (pH 8.8) containing 6 mol/L urea, 30% glycerol, 2% sodium dodecyl sulfate, 0.002% bromophenol blue, and 80 mmol/L dithiothreitol or 0.025% iodoacetamide. The gel strips were then separated in 12% polyacrylamide gels to perform the second dimensional electrophoresis. The 2-DE gels were then exposed to Coomassie Brilliant Blue G-250 (CBBG-250) or silver staining. Duplicated 2-DE gels were also transferred on polyvinylidene difluoride membrane and then used for the detection of citrullinated proteins using an antibody to modified citrulline. The protein spots of immunoblotting-matched citrullinated proteins were subjected to in-gel trypsin digestion, and digested peptides were analyzed by matrix-assisted laser desorption/ionization-time of flight (MALDI-TOF) mass spectrometry (the Proteomics Service by Genomine, Pohang, Republic of Korea). The obtained peptide mass fingerprints spectra were analyzed by searching the Genomine local database and the National Centre for Biotechnology Information, nonredundant protein database with ProFound (http://prowl. rockefeller.edu/prowl-cgi/profound.exe). Statistical Analysis Quantitative results were expressed as means ± SEM. The probability of statistical differences between control and scrapie-infected groups was determined by a one-way analysis of variance test as indicated. Differences were considered significant at P < 0.001, P < 0.01, and P < 0.05. Results Increased Accumulation of Citrullinated Proteins in Various Brain Regions of Scrapie-Infected Mice We first used Western blot analysis as described in the Materials and Methods to examine the citrullinated proteins from different brain regions of control and ME7 scrapie-infected mice. Total proteins were extracted from whole brains as well as from various dissected brain regions including cerebral cortex, hippocampus, striatum, cerebellum, and brain stem of control and scrapie-infected mice. In general, citrullinated proteins in most brain sections of scrapie-infected mice were markedly increased compared to controls (Figure 1
Next, we performed immunohistochemical staining of citrullinated proteins in different brain sections of control and scrapie-infected mice. As shown in Figure 2
Up-Regulation of PAD2 Expression in Various Brain Regions from Scrapie-Infected Mice Posttranslational modification of protein arginine residues to citrulline is mediated by PAD2 enzyme in the brain. Therefore, we examined whether the expression levels of PAD2 in the brains are increased after ME7 scrapie infection. As can be seen in Figure 3A
In the next experiment, we measured expression levels of PAD2 mRNA in whole brains of both control and ME7 scrapie-infected mice using PAD2-specific primers as described in the Materials and Methods. As can be seen in Figure 3C Increased Immunofluorescence Staining of PAD2 in Reactive Astrocytes in Brains of Scrapie-Infected Mice Next, to confirm the increased PAD2 expression and to determine the cellular localization of PAD2, immunohistochemical analysis was performed using various brain sections from control and scrapie-infected mice (Figure 4, A–E and F–J
Elevated PAD2 Enzyme Activity in the Brains of Scrapie-Infected Mice To investigate whether the increase in citrullinated proteins is attributable to higher levels of PAD2 enzyme activity and whether the increased PAD2 expression is correlated with its enzyme activity in scrapie-infected mice, we analyzed PAD2 enzyme activity in the brain homogenates of various sections from both control and ME7 scrapie-infected mice using benzoyl-l-arginine ethyl ester as a substrate as previously described.9 PAD2 enzyme activity was significantly increased approximately twofold in whole brains as well as in hippocampus, striatum, and brain stem of scrapie-infected brains compared to controls (Figure 6A)
Identification of Citrullinated Proteins by 2-DE and MALDI-TOF Mass Spectrometry For identification of various citrullinated proteins in scrapie-infected brains, we performed 2-DE analysis using whole brains as well as three different brain regions: hippocampus, cerebellum, and brain stem. We chose these three regions because i) hippocampus is the most damaged brain region, ii) cerebellum showed a marked increase in citrullinated bands between 100 kDa and 150 kDa, and iii) brain stem has shown the highest expression of PAD2 after infection with the ME7 scrapie strain. Figure 7
To identify the citrullinated spots, we analyzed peptide spots by MALDI-TOF mass spectrometer. Identified citrullinated proteins in the brains of scrapie-infected mice are summarized in Table 1. We have found some known citrullinated proteins including GFAP and MBP as well as new substrates for PAD2 including neuron-specific enolase (NSE; 2-phospho-d-glycerate hydrolase), fructose 1,6-bisphosphate aldolase A and C (ALDC), and mitochondrial malate dehydrogenase 2 (MDH2), and voltage-dependent anion channel 1 (VDAC1).
Expression Levels of Identified Citrullinated Proteins; Aldolase C, Neuron-Specific Enolase, MBP, and GFAP Based on the result of MALDI-TOF analysis, we performed Western blot analysis to determine the expression pattern of identified citrullinated proteins in control and scrapie-infected brains. As shown in Figure 8
Discussion It has been postulated that citrullination of proteins has important effects on their structure and functions. Citrullination, an irreversible posttranslational modification, has been associated with the pathogenesis of several neurodegenerative diseases including AD and MS.15,17 Citrullinated proteins in these diseases are thought to play a role during disease initiation and/or disease progression. The mouse models of neurodegenerative diseases provide a rapid and inexpensive means of studying pathogenesis and pathology of human diseases. In the present study, we demonstrated for the first time that protein citrullination occurs in a widely used model of prion diseases, ie, ME7 scrapie-infected mice. PAD enzymes have been shown to increase in various abnormal conditions in vivo including transgenic animal models of demyelinating diseases,25 optic nerve damage in glaucoma,26 and in hippocampi of AD patients.15 However, the regulatory mechanism of PAD2 expression and of the induction of citrullinated proteins involved in the pathogenesis of various diseases has not been clarified. Using a model system of scrapie-infected mice provides a number of advantages in that scrapie strains have specific parameters of incubation period, location of histopathological changes, and mouse strain susceptibility. Therefore, the combination of scrapie strain-mouse strain may give an area-specific difference in the expression pattern of PAD2 and hypercitrullinated proteins that can be correlated with histopathological changes in each brain region. The situation is more complex with human disease because of different or even unknown causes and the inability to assess brain changes during the course of the disease. However, studies with the mouse models of scrapie can provide a basis for studying citrullination in postmortem tissue from a variety of diseases. An important aspect of citrullination in vivo and in vitro is that PAD enzymes require ~100-fold higher than the normal intracellular Ca2+ level for its activation.7 PrPSc is associated with elevation of intracellular Ca2+ released from endoplasmic reticulum in neuroblastoma cells.27 PrP 106-126 peptide that shares several characteristics with PrPSc induces Ca2+ release from endoplasmic reticulum and mitochondria.28,29 These reports suggest that intracellular Ca2+ is increased in a variety of cells in the brains of scrapie-infected mice. The increase in intracellular Ca2+ during scrapie infection would augment the activity of PAD2, which, in turn, would lead to citrullination of various proteins. In addition, malfunctioning of some of these citrullinated proteins could play a role in the pathogenesis of the pathological changes that are seen in prion diseases. This scenario is supported by our findings of increased PAD2 and citrullinated proteins combined with the above-noted reports on the relationship between Ca2+ metabolism and scrapie. Because the current knowledge of the molecular features of PAD enzymes is limited, it is still unclear whether activation of PAD2 is a cause of or an effect of the progression of prion diseases. In a previous article, PAD2 was increased and accumulated in the hippocampus during the progress of AD.15 This finding suggests that because PAD2 was increased even during early stages of AD, PAD2 activation may be related to onset of neurodegenerative change in this disease. It has been suggested that the activation of PADs is induced by elevation of intracellular calcium levels or leakage of the enzyme to the extracellular space as a result of cell membrane disruption.30,31 Although the increased intracellular calcium levels appear to be the major regulator of PADs, it has been shown that some hormones, including estrogen, progesterone, and insulin, and other molecules that induce differentiation of cells regulate the activity of PAD2 and other PAD isotypes.32 Moreover, PAD2 activity is enhanced in a reducing environment,33,34 indicating that PAD activity can be up-regulated by modulation of disulfide bonds. Thus, these data show that the regulation of PAD2 activity is highly complex with multiple interlocking control points. Results of Western blot analysis using an antibody to citrullinated proteins have shown a variety of strong bands between 10 kDa to 150 kDa. A number of these were markedly increased in scrapie compared to control brain regions. We analyzed homogenates of whole brain, brain stem, and cerebellum from control and scrapie-infected mice by 2-DE and MALDI-TOF mass spectrometry analyses that yielded 13 distinct citrullinated proteins (Table 1). We could not establish the identity of the bands in brain stem and cerebellum between 100 kDa to 150 kDa using 2-DE. Three distinct citrullinated proteins were previously demonstrated: GFAP in AD,15 MBP in MS,35 and α-enolase in rheumatoid arthritis (RA).36 These proteins relate to energy production pathway and to cellular structure. GFAP and MBP are well known to show increases in citrullination in degenerative disorders. In ME7-infected mice, there were pronounced increases in the levels of citrullinated GFAP compared to controls in all brain regions tested (Figure 1) Interestingly, we found that energy regulation-related proteins such as enolases, aldolases, MDH2, and VDAC1 can be citrullinated by PAD2 in scrapie. α-Enolase, a glycolytic enzyme, has been identified as an autoantigen in diseases such as MS41 and Hashimoto’s encephalopathy.42 NSE has been used as a pathogenic marker in various neurological diseases including MS,43 acute ischemic stroke,44 and RA.36,45 In addition, previous reports showed an early elevation of NSE in cerebrospinal fluid of Creutzfeldt-Jakob disease (CJD) patients, which decreased with disease duration, and this early elevation is considered to support the diagnosis of CJD.46,47,48 We also examined the expression level of NSE in brains of scrapie-infected mice and the results showed slightly decreased levels in hippocampus and cerebellum of scrapie brain compared to controls; levels in other brain regions were similar in control and scrapie (Figure 8) Aldolase A is suggested as a candidate autoantigen in RA45 and in AD,49 and its deficiency is associated with a hemolytic anemia.50 ALDC has been termed “scrapie-responsive protein 2 (scrg2),” and its mRNA is increased in scrapie infection.51,52 We also confirmed an increase of ALDC in scrapie-infected mice using Western blot (Figure 8) Finally, we have identified more candidate citrullinated proteins such as cofilin 1, peptidylprolyl isomerase A, and peroxiredoxin 1. Cofilin 1 is an actin-binding protein that modulates neuronal actin dynamics and synaptic plasticity.57,58 Peptidylprolyl isomerase A has multiple roles in protein refolding, signal transduction, and cell cycle regulation.59 Peroxiredoxin 1 is a thiol-specific multifunctional antioxidant enzyme whose major role is a defense against oxidative stress through peroxidase activity.60 In a recent report, the expression of this gene was increased by ~30% in 139A scrapie-infected mice.61 Further investigations are required to characterize these candidate citrullinated proteins and their physiological functions. Herein we demonstrated the increased expression of PAD2 and identified a number of citrullinated proteins in the ME7-infected mouse model of prion diseases. Whether the citrullination of these proteins has physiological consequences remains unknown. Nevertheless, PAD2 may play a role in the onset and progression of prion diseases by abnormal disruption of Ca2+ homeostasis, and/or by increasing citrullinated proteins. Furthermore, citrullinated proteins may serve as a useful marker for human neurodegenerative diseases. The further study of these citrullinated proteins may provide more definitive answers about molecular functions and pathological mechanisms in prion diseases, including human neurodegenerative disorders. Footnotes Address reprint requests to Professor Eun-Kyoung Choi, Laboratory of Cellular Aging and Neurodegeneration, Ilsong Institute of Life Science, Hallym University, Anyang, Gyeonggi-do 431-060, Republic of Korea. E-mail: ekchoi/at/hallym.ac.kr. Supported by the Korea Research Foundation grant funded by Korean Government (MOEHRD, Basic Research Promotion Fund) (KRF-2006- 331-E00287). B.J. and E.K. contributed equally to this article. References
|
PubMed related articles
Your browsing activity is empty. Activity recording is turned off. |
|||||||||||||||||||||
Proc Natl Acad Sci U S A. 1998 Nov 10; 95(23):13363-83.
[Proc Natl Acad Sci U S A. 1998]Nat Rev Mol Cell Biol. 2007 Jul; 8(7):552-61.
[Nat Rev Mol Cell Biol. 2007]Proc Natl Acad Sci U S A. 2004 Aug 17; 101(33):12271-6.
[Proc Natl Acad Sci U S A. 2004]Neurology. 1996 Sep; 47(3):741-50.
[Neurology. 1996]FEBS Lett. 2007 Jun 26; 581(16):3019-26.
[FEBS Lett. 2007]J Biol Chem. 1989 Oct 25; 264(30):18119-27.
[J Biol Chem. 1989]Bioessays. 2003 Nov; 25(11):1106-18.
[Bioessays. 2003]J Biol Chem. 1996 Nov 29; 271(48):30709-16.
[J Biol Chem. 1996]J Biol Chem. 2001 Jun 1; 276(22):19197-204.
[J Biol Chem. 2001]Anal Biochem. 1992 May 15; 203(1):94-100.
[Anal Biochem. 1992]Methods Enzymol. 1984; 107():624-31.
[Methods Enzymol. 1984]Biochim Biophys Acta. 1988 Sep 8; 966(3):375-83.
[Biochim Biophys Acta. 1988]Arch Biochem Biophys. 2002 Nov 1; 407(1):25-31.
[Arch Biochem Biophys. 2002]Mech Ageing Dev. 1998 Jan 30; 100(2):133-43.
[Mech Ageing Dev. 1998]J Chem Neuroanat. 1992 Mar-Apr; 5(2):159-68.
[J Chem Neuroanat. 1992]Cell Biol Int. 1993 May; 17(5):525-32.
[Cell Biol Int. 1993]Neurosci Lett. 1999 Oct 15; 274(1):53-5.
[Neurosci Lett. 1999]Biochim Biophys Acta. 1988 Sep 8; 966(3):375-83.
[Biochim Biophys Acta. 1988]Acta Neuropathol. 1985; 67(3-4):309-14.
[Acta Neuropathol. 1985]J Neurocytol. 2001 Dec; 30(12):957-65.
[J Neurocytol. 2001]J Neurosci Res. 2005 Apr 1; 80(1):120-8.
[J Neurosci Res. 2005]Neurochem Res. 2007 Feb; 32(2):251-6.
[Neurochem Res. 2007]J Neurochem. 2002 Apr; 81(2):335-43.
[J Neurochem. 2002]Curr Eye Res. 2006 Dec; 31(12):1063-71.
[Curr Eye Res. 2006]J Neurosci Res. 2005 Apr 1; 80(1):120-8.
[J Neurosci Res. 2005]Bioessays. 2003 Nov; 25(11):1106-18.
[Bioessays. 2003]EMBO J. 2003 Oct 15; 22(20):5435-45.
[EMBO J. 2003]J Biol Chem. 2001 Nov 23; 276(47):43516-23.
[J Biol Chem. 2001]Neurobiol Dis. 2006 Sep; 23(3):669-78.
[Neurobiol Dis. 2006]J Neurosci Res. 2005 Apr 1; 80(1):120-8.
[J Neurosci Res. 2005]Clin Chim Acta. 2004 Dec; 350(1-2):17-34.
[Clin Chim Acta. 2004]Int J Cosmet Sci. 2007 Jun; 29(3):147-68.
[Int J Cosmet Sci. 2007]J Biochem. 1981 Jan; 89(1):257-63.
[J Biochem. 1981]Biochim Biophys Acta. 1983 Jun 29; 745(3):285-91.
[Biochim Biophys Acta. 1983]J Neurosci Res. 2005 Apr 1; 80(1):120-8.
[J Neurosci Res. 2005]Ann Neurol. 1996 Jul; 40(1):18-24.
[Ann Neurol. 1996]Arthritis Res Ther. 2005; 7(6):R1421-9.
[Arthritis Res Ther. 2005]J Biol Chem. 1996 Nov 29; 271(48):30709-16.
[J Biol Chem. 1996]Biochemistry. 2000 May 9; 39(18):5374-81.
[Biochemistry. 2000]J Virol. 1991 Sep; 65(9):4759-68.
[J Virol. 1991]Muscle Nerve. 1992 Nov; 15(11):1234-9.
[Muscle Nerve. 1992]Arch Neurol. 2002 Nov; 59(11):1811-4.
[Arch Neurol. 2002]Proteomics. 2004 Jul; 4(7):2184-94.
[Proteomics. 2004]J Neuroimmunol. 2007 Apr; 185(1-2):195-200.
[J Neuroimmunol. 2007]J Clin Immunol. 2007 Jul; 27(4):388-96.
[J Clin Immunol. 2007]Cerebrovasc Dis. 2005; 20(4):213-9.
[Cerebrovasc Dis. 2005]Arthritis Res Ther. 2005; 7(6):R1421-9.
[Arthritis Res Ther. 2005]Ann Rheum Dis. 1999 Mar; 58(3):169-74.
[Ann Rheum Dis. 1999]J Immunol. 2005 Sep 1; 175(5):3439-45.
[J Immunol. 2005]Proc Natl Acad Sci U S A. 1987 Dec; 84(23):8623-7.
[Proc Natl Acad Sci U S A. 1987]Brain Res Mol Brain Res. 2000 Mar 10; 76(1):173-9.
[Brain Res Mol Brain Res. 2000]J Biol Chem. 1998 Mar 27; 273(13):7691-7.
[J Biol Chem. 1998]J Biol Chem. 1999 Nov 26; 274(48):33827-30.
[J Biol Chem. 1999]Proc Natl Acad Sci U S A. 2005 Nov 1; 102(44):16072-7.
[Proc Natl Acad Sci U S A. 2005]Cell Mol Life Sci. 1999 Mar; 55(3):423-36.
[Cell Mol Life Sci. 1999]Antioxid Redox Signal. 2005 May-Jun; 7(5-6):768-77.
[Antioxid Redox Signal. 2005]J Proteome Res. 2006 Aug; 5(8):1948-58.
[J Proteome Res. 2006]